Advertisement
Canada markets open in 28 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7296
    -0.0001 (-0.02%)
     

  • CRUDE OIL

    82.86
    +0.05 (+0.06%)
     

  • Bitcoin CAD

    86,904.02
    -4,078.51 (-4.48%)
     

  • CMC Crypto 200

    1,356.90
    -25.68 (-1.86%)
     

  • GOLD FUTURES

    2,346.30
    +7.90 (+0.34%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,378.50
    -286.00 (-1.62%)
     

  • VOLATILITY

    16.77
    +0.80 (+5.00%)
     

  • FTSE

    8,073.24
    +32.86 (+0.41%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6818
    -0.0001 (-0.01%)
     
MARKETS LIVE BLOG:

STOCK FUTURES SLIDE AFTER META'S REALITY CHECK, WITH GDP ON DECK

Owner of Facebook and Instagram plans to spend up to US$10B on AI infrastructure investments

A Savvy Biotech Investor Is Betting Up To $25 Million Dollars On This $8 Stock Returning 250%... Or More?

Baystreet.ca
Updated

- Top-notch Great Point Partners is investing up to $25 million in Orgenesis' (ORGS) manufacturing subsidiary to enable global expansion. Company is already generating growing revenue, and this specialist healthcare fund investment substantiates the ORGS growth opportunity - Demand for CDMOs, like ORGS, is growing as more cell therapies (like gene therapies and CAR-T cells) come to market in the coming years. Great Point's investment may signal they see upside potential of 3X or more, ... Click here to view full article